SCHEMBL25810523

SCHEMBL25810523

CNC(=O)c1cccc(CC(=O)OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.55
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
MRGPRX4 Q96LA9 2/20 0.51
LOXL2 Q9Y4K0 1/20 0.47
CYP4F2 P78329 3/20 0.46
CYP4A11 Q02928 3/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 1/20 0.46
GFER P55789 1/20 0.46
CFD P00746 1/20 0.46
HSP90AB1 P08238 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
MMP13 P45452 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63816 0.84 SLC7A5 (0.52) SLC7A5HDAC8HDAC6MRGPRX4LOXL2
SCHEMBL2964543 0.83 LOXL2 (0.68) SLC7A5MRGPRX4LOXL2CYP4F2CYP4A11
SCHEMBL30489978 0.83 SLC7A5 (0.57) SLC7A5MRGPRX4LOXL2RAB9ASMN1; SMN2
SCHEMBL5437533 0.83 SLC7A5 (0.61) SLC7A5HDAC8HDAC6MRGPRX4ALDH1A1
SCHEMBL8057216 0.83 SLC7A5 (0.57) SLC7A5LOXL2CYP4F2CYP4A11ALDH1A1
SCHEMBL479999 0.83 SLC7A5 (0.57) SLC7A5MRGPRX4LOXL2RAB9ASMN1; SMN2
SCHEMBL12400239 0.82 SLC7A5 (0.68) SLC7A5LOXL2CYP4F2CYP4A11ALDH1A1
SCHEMBL24031215 0.82 SLC7A5 (0.56) SLC7A5LOXL2CYP4F2CYP4A11ALDH1A1
SCHEMBL3451761 0.82 SLC7A5 (0.56) SLC7A5LOXL2CYP4F2CYP4A11ALDH1A1
SCHEMBL10283538 0.82 MRGPRX4 (0.59) SLC7A5HDAC8HDAC6MRGPRX4LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 US disclosed
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 US disclosed
CN-115340555-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-11-15 CN disclosed
CN-113173924-B Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-07-19 CN disclosed
CN-113173924-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2021-07-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof CDK9, CDK7, CDK8 SLC7A5 4282/4885HDAC8 58/4885HDAC6 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.